ITHACA, N.Y. – March 24, 2014 - Rheonix, Inc., a developer of fully automated molecular testing solutions, announced today that it has been invited to exhibit at “The Future of In-Vitro Diagnostics.” The exclusive conference, held April 10, 2014 in Menlo Park/Palo Alto, CA, is hosted by Siemens Venture Capital, the investment arm of Siemens, and Siemens Healthcare.
The fifth annual conference brings together over 100 CEOs and CTOs, investors, key opinion leaders, and clinicians from the in vitro diagnostic industry along with Siemens’ executive and technical teams. Only companies identified by Siemens as among “the most attractive in their field” were invited. The invited companies will present, exhibit, and attendees will be highlighted in the conference booklet and mentioned at the event.
Rheonix’s innovative products fully automate the molecular analysis of a wide variety of samples, such as tissue, swabs, or blood, for assays ranging from oncology to infectious disease. Rheonix’s core product is a microfluidic device called the Chemistry and Reagent Device, or Rheonix CARD® , a simple, disposable cartridge that accepts a raw sample, applied by a laboratory technician. The CARD is then interfaced with Rheonix’s instrument, the EncompassMDx™, which controls the CARD’s performance of molecular assays from start to finish without human intervention. The resulting highly multiplexed assays are able to transform data into clinically relevant diagnostic information more effectively than conventional approaches. The EncompassMDx processes multiple CARD’s simultaneously, which will allow clinical labs to increase their productivity while maintaining existing staffing levels.
Rheonix’s products simplify the entire molecular diagnostic testing process by eliminating the need for multiple pieces of equipment, decreasing hands-on technician time, and producing results quickly, more efficiently, and more cost-effectively, while eliminating opportunity for human error. Rheonix’s approach addresses a key need of patients, physicians, and laboratories for access to easy to use devices that are capable of delivering more information in a costeffective manner in everyday settings.
“Our invitation to the Siemens healthcare conference is a testament to the value, innovation, quality, and many unique attributes of our CARD microfluidic devices,” said Tony Eisenhut, Rheonix president. “We have created a fully-automated, elegantly simple approach to molecular diagnostic testing that we believe will benefit all aspects of the marketplace, including patients, physicians, laboratories, and payors. We look forward to continuing to share our story with clinicians, investors, and the other distinguished guests at the Siemens conference.”
Initial applications currently targeted by Rheonix include STIs (sexually transmitted infections), HAIs (hospital-acquired infections), respiratory infections, and GI (gastrointestinal) infections.
The conference will be held at the Quadras Conference Center in Menlo Park, CA.
For more information on the conference, visit www.seeuthere.com/InVitroDiagnosticsConference